Aktuelle Studien Rekrutierend: Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk, HR+/HER2- early breast cancer __________________________________________________________________________________________________________ Rekrutierend: PlanB-LT-FU-Registry Long term follow up registry for outcome evaluation in HR-positive/HER2 negative early breast cancer patients treated within the prospective PlanB study and relapse free after 5 years of endocrine therapy ___________________________________________________________________________________________________________ Im Follow Up: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer Haben Sie Interesse an der Teilnahme an einer klinischen Studie der WSG? Dann bewerben Sie sich mit Hilfe unseres Fragebogens!